
Bristol-Myers Squibb has announced updated results from trialing Opdivo (nivolumab) plus Yervoy (ipilimumab) versus sunitinib in patients with previously untreated …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

